| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.07 | 0.1 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.1 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |